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Abstract
Background: Cancer cells exhibit an altered metabolism, which is characterized by a preference for aerobic
glycolysis more than mitochondrial oxidation of pyruvate. Mitochondrial pyruvate carrier 1 (MPC1) and
mitochondrial pyruvate carrier 2 (MPC2) play a bottleneck role by transporting pyruvate into mitochondrial through
the mitochondrial inner membrane. Therefore, their protein expression in cancers may be of clinical consequences.
There are studies showing low levels of MPC1 expression in colon, kidney and lung cancers, and the expression of
MPC1 correlates with poor prognosis. However, the expression status of MPC1 and MPC2 in prostate cancer (PCA)
is unclear.
Methods: In this study, expression of MPC1 and MPC2 in LNCaP and DU145 prostate cancer cell lines was
examined by immunocytochemistry (ICC) and Western blotting. Compared to the LNCaP cells, lower levels of MPC1
and MPC2 expression in the DU145 cell line was identified. We then extended our study to 88 patients with
prostate cancer who underwent transurethral electro-vaporization of prostate or radical prostatectomy at the First
Affiliated Hospital of Zhengzhou University, Henan, China. Patient-derived paraffin embedded PCA specimens were
collected for immunohistochemistry (IHC). Correlations with clinicopathologic factors were evaluated by Chi-square
or Fisher´s exact probability tests. Overall survival (OS) rates were determined using the Kaplan-Meier estimator. The
Cox proportional hazard regression model was used in univariate analysis and multivariate analysis to identify
factors significantly correlated with prognosis.
Results: Linear regression analysis revealed that MPC1 expression level was positively correlated with MPC2
expression (r = 0.375, P = 0.006) in the prostate cancers. MPC1 expression was negatively associated with UICC stage
(P = 0.031). While UICC stage (P < 0.001) and lymph node metastasis (P = 0.002) were negatively associated with
MPC2 expression. Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS
(P < 0.05). The multivariate analysis showed that both MPC1 and MPC2 expressions in PCA were independent
prognostic factors for higher OS (For MPC1: RR = 0.654, 95% CI: 0.621-0690, P < 0.001; For MPC2: RR = 0.696,
95% CI: 0.660-0.734, P < 0.001).
Conclusions: Our study indicates that MPC1 and MPC2 expressions are of prognostic values in PCAs and that
positive expression of MPC1 or MPC2 is a predictor of favorable outcome.
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Background
Prostate cancer (PCA) is one of the most common can-
cers and the sixth leading cause of cancer death among
men throughout the world [1]. Over the last decade, the
morbidity of PCA was steadily increased in China, due
to the changing in dietary pattern and Westernized life-
style [2]. Nowadays, serum level of prostate specific anti-
gen (PSA), digital rectal examination (DRE) and
diagnostic imaging techniques such as ultrasound and
MRI are used as methods for PCA diagnosis. As a highly
heterogeneous disease, PCA may vary from slow grow-
ing indolent tumor to rapidly progressing highly aggres-
sive carcinoma, which is associated with significant
morbidity and mortality [3]. It is realized now that it is
important to examine the conceivable biomarkers of
PCA patients to make individualized treatment possible.
Metabolism in normal condition relies on two differ-
ent pathways, glycolysis and oxidative phosphorylation
(OXPHOS) to generate ATP and produce energy [4].
Glycolysis is a process that converts glucose into lactate,
which generates 2 molecules of ATP per molecule of
glucose. In normoxia condition, cellular glucose is con-
verted into pyruvate, which is carried into mitochondrial
and oxidized, a process of OXPHOS, from which 36
ATP molecules are generated. Mitochondrion plays a
significant role in OXPHOS. In cancer cells, aerobic gly-
colysis holds the main pathway to produce energy, called
Warburg effect [5]. This way is quicker and suitable for
cancer tissues proliferation [6]. Although it yields less
ATP than OXPHOS, this is more suitable for the growth
of cancer cells, since higher energy production may
worsen the body situation [7].
Pyruvate is a hub metabolite for glucose, lipid and
amino acid. The cellular fate of pyruvate determines
whether glycolysis is followed by OXPHOS, or by lactic
fermentation. It has been known that the existence of
mitochondrial pyruvate carrier allows the pyruvate en-
tering into the mitochondrial matrix, and the functions
of the MPC molecules are recently verified simultan-
eously by two groups [8, 9]. These studies have shown
that MPC1 and MPC2 are two paralogous subunits
composing the heteromeric complex of MPC in mam-
mals, and the MPC complex is located in the inner
mitochondrial membrane. Moreover, it has shown in
some studies that the expression levels of MPC1 and
MPC2 in cancers are decreased, and low expression is
correlated with poor survival in multiple cancers, includ-
ing colon, kidney and lung [10], illustrating the regula-
tion of MPC complex is pivotal for tumor cell growth.
Thus assessment of the expression of the MPC may be
of significance in the understanding of cancer metabolic
alterations.
In this study, we verified variable MPC1 and MPC2
expressions in two different prostate cancer cell lines
(LNCaP and DU145) and found that the aggressive DU-
145 cell line expressed lower levels of MPC1 and MPC2.
Then we extended our study in analyzing the expression
status of MPC1 and MPC2 in a series of 88 PCA sam-




LNCaP and DU145 cell lines were purchased directly
from American Type Culture Collection (ATCC), USA
in 2006. The cells were expanded for 4 passages, and all
the cells were preserved in nitrogen before use in this
study. All the cells were authenticated in October 2016
by Sangon Biotech Co., Ltd. (Shanghai, China) using
MicroreaderTM21 ID System to analyze 9 short tandem
repeat (STR) loci, showing that all these cells matched
their original STR profiles. All the cells were routinely
tested and confirmed to be mycoplasma free. Cells were
cultivated in PRMI 1640 medium (GibcoTM, 11835-
063) supplemented with 10% fetal bovine serum (FBS)
(GibcoTM, 10500-064), 100units/ml penicillin and
100 mg/ml streptomycin (Life Technologies, 15140122)
at 37 °C in a humidified 5% CO2 incubator.
Cell block preparation
For each cell line, the cells in 80% confluent were har-
vested by mechanical scraping, and cells were washed
twice with ice-cold phosphate-buffered saline (PBS) and
collected by centrifuged at 2000 rpm for 10 minutes.
Three drops of plasma and two drops of thrombin were
added to the sedimentation and the contents were care-
fully mixed by rotating tube for one minute until the co-
agulation was formed. 4% buffered formaldehyde was
added to the coagulation for cell fixation in 30 minutes.
The coagulated mass was then wrapped in a linen paper,
put in a labeled cassette and placed in 4% buffered for-
maldehyde. The material was paraffin-embedded to
make cytoblock before being cut into 4 mm paraffin sec-
tions for immunocytochemistry (ICC).
Western blotting
All the cells were harvested by cell scraper when cells
grew 80% confluent and the cells in suspension were
centrifuged at 1000 rpm for 5 minutes. After washed
with ice-cold PBS twice, the cells were dissolved with
lysis buffer containing RIPA buffer (Thermo scientific,
89900) and 1% protease inhibitor cocktail (Thermo sci-
entific, 1862209) by pipetting gently up and down, put
on ice before spun down at 13000 rpm for 10 minutes at
4 °C to release total protein in the supernatant. Total
protein concentration was measured by the Quick
StartTM Bradford (Bio-Rad, 500-0205). Equal amount of
proteins from each sample in sodium dodecyl sulfate
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(SDS) loading buffer was boiled for 10 minutes at 100 °C,
and the protein samples were subjected to 10% SDS-
PAGE electrophoresis and then electro-transferred to
high-quality polyvinylidene difluoride (PVDF) membrane
in a Trans-Blot apparatus (Bio-rad, Hercules, CA). The
membrane was blocked with 5% fat-free milk for 2 hour at
room temperature and incubated overnight at 4 °C with
rabbit anti-human MPC1 antibody (1:500, NOVUS,
NBP1-91706) and MPC2 antibody (1:1000, Abcam,
ab10391). After washing with TBST (TBS with 0.1%
Tween), the blot was incubated with corresponding sec-
ondary antibodies conjugated with horseradish
peroxidase-conjugated (HRP) for 2 hours at room
temperature. Finally, the blot was visualized using an
enhanced chemiluminescence detection kit (ECL,
Amersham) and analyzed by Image Lab 2.0 Software
(Bio-Rad Laboratories Inc, USA). The protein band
was normalized to α-Tublin.
Patients
Paraffin embedded samples from 88 PCA patients were
enrolled in this study. All the patients were admitted to
the First Affiliated Hospital of Zhengzhou University
from December 2005 to December 2011. Inclusion cri-
teria: (1) not received surgical resection or radio-/
chemo-/hormonal treatment before tissue collection; (2)
with full information of clinical/TNM staging; (3) with
confirmed diagnosis with prostate cancer by postopera-
tive pathological examination. The detailed clinicopatho-
logical features are summarized in Table 1. The ages
rank from 55 to 92 years old (average age = 71 years). A
further TNM staging following the American Joint Com-
mittee on Cancer (AJCC) standard identified 67 stage II
patients, 21 stage III and IV patients. Lymph node me-
tastasis was discovered in 14 patients. A further differen-
tiation score based on Gleason system [11] showed 27
low (<7), 41 moderate (=7) and 20 (>7) high grade tu-
mors. The distance metastasis was identified in 25 cases.
Median prostatic specific antigen (PSA) level: 77.56 ng/
ml (0.2–100.00). Patients were followed up from the
confirmed date of diagnosis until death or 1 Jan. 2015.
Two pathologists at the Department of Pathology of the
First Affiliated Hospital of Zhengzhou University
reviewed and diagnosed all the specimens.
Immunocytochemistry (ICC) and Immunohistochemistry
(IHC)
ICC and IHC detection of MPC1 and MPC2 were per-
formed with the use of the Dako Envision FLEX+ system
(K8012, Dako, Glostrup, Denmark). Paraffin sections
were deparaffinized. Microwaving antigen retrieval was
performed in citrate buffer (pH 6.0) for 15 min then
returned to room temperature and washed in PBS.
Blocking was operated by peroxidase blocking (Dako)
for 5 minutes. The slides were incubated at 4 °C over-
night with MPC1 antibody (1:700, NOVUS, NBP1-
91706) and MPC2 antibody (1:300, Abcam, ab10391),
following with second antibody linker incubation for
15 minutes before HRP was added and incubated for
30 minutes at room temperature. Slides were then
stained with 3, 39-diaminobenzidine tetrahydrochloride
(DAB) for 10 minutes and counterstained with
hematoxylin, dehydrated and mounted.
IHC scoring system
MPC1 and MPC2 immunodetections were evaluated by
two pathologists, who were blinded to the outcomes of
patients. The scores were grouped according to intensity
and extent of staining. The extent of positivity was
scored as follows: 0, no positive cells; 1, <10% positive
cells; 2, 10–50% positive cells; and 3, >50% positive cells.
The intensity was scored as follows: 0, no positive cells;
1, weak staining; 2, moderate staining; and 3, strong
staining. The immunohistochemical staining score was
multiplying extent by intensity (0, 1, 2, 3, 4, 6 or 9). For
statistical analyses, a score of 0 was designated negative,
the score of 1 and 2 as weakly positive, and the score of
3-9 as positive.
Statistical analyses
SPSS 17.0 software (SPSS Inc, Chicago, IL, United
States) was used for data analyses. Associations between
categorical variables were assessed by Chi-square tests
(Pearson as appropriate) or Fisher`s exact probabilities.
The relationship between MPC1 and MPC2 expressions
was evaluated by linear regression analysis. Survival ana-
lysis was estimated using the Kaplan-Meier method, and
groups were compared with log-rank tests. For all the
analyses, associations were considered to be significant if
the P value was smaller than 0.05. Cox regression
method was used to analyze the factors of prognosis.
Table 1 Clinical and pathologic characteristics for 88 patients
with malignant prostate cancer
Variable: Median (range) or NO. of patient
Age: 71 years (55–92)
Preoperative PSA: 77.56 ng/ml (0.2–100.00)
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Results
Expression of MPC1 and MPC2 in prostate cancer cell
lines
ICC identified variable MPC1 and MPC2 protein expres-
sions in the prostate cancer cell lines LNCaP and
DU145 (Fig. 1A, a, b, c, d). Comparatively, it was discov-
ered that DU145 cell line showed the lowest expression
of both MPC1 and MPC2 (Fig. 1A c, d), and LNCaP cell
line was strongly positive (Fig. 1A a, b) for these two
proteins. Similar levels of the MPC1 and MPC2 protein
expressions were confirmed by Western blotting in these
cell lines as well, with immunoreactive bands of 10 kDa
and 12 kDa for MPC1 and MPC2, respectively (Fig. 1b).
MPC expression in human PCA tissues
Both MPC1 and MPC2 immunohistochemical reactiv-
ities were confined to cytoplasm of cells. Typical diffused
cytoplasmic staining of the MPC1 protein is shown in
Fig. 2 and Fig. 3 shows typical cytoplasmic MPC2 ex-
pression in a PCA. It was discovered that a large number
Fig. 1 ICC and Western blotting of MPC1 and MPC2 expression in prostate cancer cell lines. a: Strong MPC1 (a) and MPC2 (b) immunoreactivities
in the LNCaP cell line; Weak MPC1 (c) and MPC2 (d) protein expression in the DU145 cell line. All the photos were taken at 400X. b: Similar levels
of MPC1 and MPC2 proteins revealed by Western blotting in these cell lines are shown as revealed with ICC shown in A, i.e.: low expression of
both MPC1 and MPC2 in DU145 cell line, compared to the protein expression in LNCaP cell line. α–tubulin was used as loading control. Right
penal shows quantified denstitometry of the Western blottings. Data are presented as mean ± SEM (n = 3 separate test). Statistical
significance: ***P < 0.001
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of tumors were negative for either MPC1 or MPC2, or
for both proteins. Out of the 88 tumors, 29(33.33%)
were positive for MPC1 protein expression, while
23(26.14%) were positive for MPC2 protein expression.
Linear regression analysis further revealed that the
MPC1 expression was positively correlated with the
MPC2 expression in the PCA tumor tissues (r = 0.348,
P =0.017; Table 2).
Fig. 2 Immunohistochemical staining of MPC1 in prostate cancer samples. The typical diffuse cytoplasmic staining of the protein can be found in
prostate cancer. a, b: MPC1 strong positivity was observed in the cytoplasm of prostate cancer cells; c, d: MPC1 weak positivity was observed in
the cytoplasm of prostate cancer cells; e, f: MPC1 negativity was observed in the cytoplasm of prostate cancer cells. The dark arrows show that
where the images in the right panel come from. The red arrows point to the tumor cells with weakly positive MPC1 protein expression.
Magnification in the left panel: 200X; Magnification in the right panel: 400X
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Clinicopathological correlation
The associations between MPC1 and MPC2 protein ex-
pression and the clinicopathological features were ana-
lyzed. As summarized in Table 3, MPC1 expression was
significantly negatively associated with UICC stage (P <
0.05). MPC1 protein positive expression was noted only
in 2/21 (9.52%) pT3- pT4 stage samples. No significant
association was found between the MPC1 protein
Fig. 3 Immunohistochemical staining of MPC2 in prostate cancer samples. The typical diffuse cytoplasmic staining of the protein can be found in
prostate cancer. a, b: MPC2 strong positivity was observed in the cytoplasm of prostate cancer cells; c, d: MPC2 weak positivity was observed in
the cytoplasm of prostate cancer cells; e, f: MPC2 negativity was observed in the cytoplasm of prostate cancer cell. The dark arrows show that
where the images in the right panel come from. The red arrows point to the tumor cells with weakly positive MPC1 protein expression.
Magnification in the left panel: 200X, Magnification in the right panel: 400X
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expression and other clinical parameters such as age,
Gleason score, lymph node metastasis, PSA and distant
metastasis. Table 4 shows that MPC2 expression is sig-
nificantly negatively associated with UICC stage and
lymph node metastasis (P < 0.05). 11/21 (52.38%) of the
pT3- pT4 PCA samples were weakly positive and nega-
tive for the MPC2 protein expression. The MPC2 pro-
tein expression was negatively associated with lymph
node metastasis, and 13 out of the 14 (92.86%) tumors
with lymph node metastases were either weakly positive
or negative for the protein.
Decreased MPC1 and MPC2 expressions in PCA are
associated with unfavorable survivals
The overall survival (OS) rate of the 88 patients
with PCA was 36.4%, with 56 deaths observed dur-
ing the follow-up period. The median duration of
follow-up was 51 months (ranging from 3 to
111 months). Kaplan-Meier survival curves and the
log-rank test demonstrated that patients with posi-
tive expression of MPC1 in the tumor had signifi-
cantly better OS than the patients with negative
MPC1 expression in the tumor (P =0.007; Fig. 4a).
The survival rate of patients with positive MPC1
protein expression was significantly higher than that
of patients with weak positive and negative MPC1
protein expression (48.3% v.s. 30.5%, respectively).
Similarly, patients with positive expression of MPC2
in the tumor had significantly better OS than did
patients with negative MPC2 expression in the
tumor (P =0.02; Fig. 4b) according to Kaplan-Meier
survival curves and the log-rank test. The survival
rate of patients with positive MPC2 protein expres-
sion was also significantly higher than that of pa-
tients with lower MPC protein expression (56.5%
v.s. 29.2%, respectively).





Positive Weak positive Negative Total
Positive 13 9 1 23
Weak positive 15 23 11 49
Negative 1 13 2 16
Total 29 45 14 88 0.006 0.375
1Pearson Chi-Square test
2Contingency coefficient
Table 3 Relationship between MPC1 expression and clinicopathological features of prostate cancer
Clinicopathologic n MPC1 expression
Variable Positive Weak positive Negative P value1
88 29(32.95%) 45(51.14%) 14(15.91%)
Age(year) 0.221
≤71 45 11(24.44%) 26(57.78%) 8(17.78%)
>71 43 18(41.86%) 19(44.19%) 6(13.95%)
Gleason score 0.682
<7 27 10(37.04%) 14(51.85%) 3(11.11%)
7–10 61 19(31.15%) 31(50.82%) 11(18.03%)
PSA (ng/ml) 0.715a
≤10 10 4(40.00%) 4(40.00%) 2(20.00%)
> 10 and≤ 20 10 2(20.00%) 6(60.00%) 2(20.00%)
> 20 68 23(33.8%) 35(51.47%) 10(14.71%)
UICC stage 0.031
pT2 67 27(40.30%) 31(46.27%) 9(13.43%)
pT3-pT4 21 2(9.52%) 14(66.67%) 5(23.81%)
lymph node metastasis 0.288
Negative 74 24(32.43%) 40(54.05%) 10(13.51%)
Positive 14 5(35.71%) 5(35.71%) 4(28.57%)
distant metastasis 0.386
Negative 63 19(30.16%) 32(50.79%) 12(19.05%)
Positive 25 10(40.00%) 13(52.00%) 2(8.00%)
1Pearson Chi-Square test; a Fisher’s exact probabilities test
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MPC1 and MPC2 expression are independent risk factors
for overall survival
Univariate analysis and multivariate analysis were per-
formed using Cox proportional hazards regression
method on the above clinicopathological parameters
with MPC1 and MPC2 expression in tumor (Table 5).
UICC stage (RR = 1.198, 95% CI: 1.095-1.311, P <
0.001),PSA (RR = 1.091,95% CI: 1.040-1.143,P < 0.001)
and Gleason score (RR = 1.635, 95% CI: 1.514-1.765, P <
0.001) are independent risk factors for overall survival
in prostate cancer patients. Moreover, MPC1 and
MPC2 expressions are also independent prognostic
factors for overall survival in PCA (For MPC1: RR =
0.654, 95% CI: 0.621-0.690, P < 0.001; For MPC2: RR =
0.696, 95% CI: 0.660-0.734, P < 0.001), while other vari-
ables including age, PSA, lymph node metastasis and dis-
tant metastasis did not contribute to overall survival
independently (P > 0.05).
Discussion
Normal adult cells maximize ATP production by metab-
olizing glucose through the OXPHOS pathway in the
mitochondria. However, the prostate is an exception.
The prostate epithelium is unique in its ability to pro-
duce, accumulate and release large amounts of citrate
into prostatic fluid [12]. But the level of citrate found in
PCA is significantly reduced. The different concentra-
tions of citrate between normal prostate and PCA indi-
cate that PCA cells may have ability to use citrate for
metabolic energy production [13], or the main pathway
for citrate synthesis is impeded.
Forty years ago, a study postulated the existence of
a mitochondrial pyruvate carrier that allows pyruvate
entry into the mitochondrial matrix [14]. And it was
revealed in 2012 that two paralogous subunits, MPC1
and MPC2, were expressed in mammals and formed
a multimeric MPC complex that controls pyruvate
transportation, which were originally known as
BRP44L and BRP44 [8, 9, 15]. Studies have shown
that when overexpressing either MPC1 or MPC2 by
itself in colorectal cancer cells, the protein fails to ac-
cumulate to a high level, suggesting that these two
proteins might need to form a complex to be stable
[10]. Another study found that the native complex
showed an apparent molecular weight of 150 kDa in
blue native gels, while the theoretical molecular
weight of a dimeric MPC complex would be around
30 kDa, indicating that multiple dimmers assemble to
form the mature carrier [16]. In humans, mutations
in MPC1 have been identified and associated with
Table 4 Relationship between MPC2 expression and clinicopathological features of prostate cancer
Clinicopathologic n MPC2 expression
Variable Positive Weak positive Negative P value1
88 23(26.14%) 49(55.68%) 16(18.18)
Age(yr) 0.652
≤71 45 10(22.22%) 27(60.00%) 8(17.78%)
>71 43 13(30.23%) 22(51.16%) 8(18.60%)
Gleason score 0.367
<7 27 9(33.33%) 12(44.44%) 6(22.22%)
7–10 61 14(22.95%) 37(60.66%) 10(16.39%)
PSA (ng/ml) 0.763a
≤10 10 4(40.00%) 5(50.00%) 1(10.00%)
> 10 and≤ 20 10 1(10.00%) 5(50.00%) 4(40.00%)
> 20 68 18(26.48%) 39(57.35%) 11(16.18%)
UICC stage 0.000
pT2 67 13(19.40%) 47(70.15%) 7(10.45%)
pT3-pT4 21 10(47.62%) 2(9.52%) 9(42.86%)
lymph node metastasis 0.002
Negative 74 22(29.73%) 43(58.11%) 9(12.16%)
Positive 14 1(7.14%) 6(42.86%) 7(50.00%)
distant metastasis 0.939
Negative 63 17(26.98%) 35(55.56%) 11(17.46%)
Positive 25 6(24.00%) 14(56.00%) 5(20.00%)
1Pearson Chi-Square test; a Fisher’s exact probabilities test
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defects in mitochondrial pyruvate metabolism, lactic
acidosis, hyperpyruvatemia, severe illness and failure
to thrive [8, 17]. Since its discovery, interest in the
MPC complex as a drug target for cancer, neuro-
logical disorders, and metabolic diseases has been ex-
tremely high. Thus, a better understanding of MPC
expression has the potential to advance our know-
ledge and impact drug discover for current public
problems.
Several studies have examined the MPC activity of
tumor by using different methodologies, and reduced
MPC function in various cancers has been reported
Fig. 4 Correlation between MPC1 and MPC2 expression and prognosis of prostate cancer patients. a: Kaplan-Meier survival curves show the positive
expression of MPC1 is significantly associated with a better overall survival in PCA. b: The Kaplan-Meier curves for overall survival rate stratified by
MPC2 show that negative MPC2 protein expression is significantly associated with shorter OS survival in PCA patients
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[18–20]. Metabolic studies by using radiolabelled
pyruvate and hyperpolarized 13C-enriched substrates
to monitor pyruvate metabolism have shown reduced
MPC metabolism pathway in cancers [18, 19]. Low
activity of MPC in cancer cells is also reported in a
real time engineered biosensor monitoring study [20].
Aerobic glycolysis is a hallmark of tumor cell metabol-
ism, and MPC has a transporter role that facilities the
pyruvate through the mitochondrial inner membrane.
Our present report was to assess the localization and ex-
pression status of MPC1 and MPC2, and further explore
their clinicopathological correlations in a series of hu-
man PCA specimens. Firstly, we detected MPC1 and
MPC2 expression in the two human prostate cancer cell
lines by ICC and Western blotting, confirming the dif-
ferent expressions of MPC1 and MPC2 in various histo-
logical subtype derived cell lines. LNCaP cells are
androgen-sensitive human prostate adenocarcinoma
cells derived from the left supraclavicular lymph node
metastasis, expressed the highest level of MPC1 and
MPC2. While the cell line DU145 is of Androgen In-
sensitive (AI) state, and this cell line has lower levels of
MPC1 and MPC2 proteins. The LNCaP cells always
show low metastatic potential, as compared to the DU-
145 cells [21]. The expression of MPC1 or MPC2 in
these cell lines indicates a potential clinical role of MPC
in PCA.
Although mitochondria have subsequently been shown
to be vital for cancer growth [22, 23], we have shown
herein that the MPC expression in PCA patient tissue is
reduced. The inclusion of the MPC adds additional com-
plexity to targeting cancer metabolism for therapy but
has the potential to explain why treatments may be
more effective in some studies than in others [24–27].
An important finding in our current study is that posi-
tive expression of MPC1 as well as MPC2 is associated
with good survival in PCA patients. These findings are
consistent with previous studies that the positive expres-
sion of MPC has a better survival in colon cancer [10].
Our data have also demonstrated that there is a posi-
tive relationship between the expression levels of MPC1
and MPC2 in PCA (r = 0.375, P = 0.006). This is consist-
ent with the conclusion that loss of either MPC1 or
MPC2 protein results in the destabilization and degrad-
ation of the other and thus loss of the MPC complex
[28, 29]. It is known that knockdown of MPC1 in pros-
tate cancer cells increases glycolysis and cell invasion
[30]. Increased glycolysis has long been demonstrated to
promote cancer progression through many ways [31, 32].
Recently, repression of MPC1 expression is found not
only to increase glycolysis through blocking glucose-
derived pyruvate entering into mitochondria, but also to
increase the supply of compensatory TCA cycle interme-
diates from glutamine, amino acids and fatty acids
[19, 33]. The TCA cycle and glycolysis provide a synthetic
precursor for lipids, proteins and nucleic acids. MPC1
down-regulation mimics a glucose-starved circumstance,
which mobilizes or activates usage of different fuel sources
to maintain the high levels of precursor pools for cell pro-
liferation, thus promoting cancer progression.
Table 5 Univariate and multivariate analysis for overall survival using Cox relative risk
Variable Univariate analysis Multivariate analysis
RR (95% CI) P value1 RR (95% CI) P value1
MPC1 expression in tumor 0.561 0.000 0.654 0.000
(0.536-0.588) (0.621-0.690)
MPC2 expression in tumor 0.558 0.000 0.696 0.000
(0.533-0.585) (0.660-0.734)
Age 0.977 0.000 0.998 0.371
(≤71 year vs >71 year) (0.973-0.981) (0.994-1.002)
UICC stage 1.34 0.000 1.198 0.000
(pT2 vs pT3-pT4) (1.259-1.427) (1.095-1.311)
Gleason score 1.769 0.000 1.635 0.000
(< 7, 7-10 ) (1.645-1.902) (1.514-1.765)
PSA(ng/ml) 1.344 0.000 1.091 0.000
(≤10, > 10 and≤ 20,> (1.286-1.405) (1.040-1.143)
lymph node metastasis 1.361 0.000 0.985 0.742
(positive vs negative) (1.253-1.478) (0.897-1.080)
distant metastasis 1.094 0.008 1.049 0.293
(positive vs negative) (1.023-1.170) (0.960-1.147)
RR relative risk; 95%CI: 95% confidence interval; 1Cox regression
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Next, we analyzed the correlation between MPC1 and
MPC2 expressions and clinicopathological parameters
including clinical outcomes. Our study shows that tumor
tissue MPC2 expression is inversely correlated with the
following PCA clinicopathologic characteristics like
UICC stage and lymph node metastasis, while MPC1 ex-
pression is inversely correlated with the UICC stage.
Therefore, we propose that the loss of MPC expression
may contribute to poorly differentiated PCAs. Another
research team found that MPC1 expression is much
lower in the primary tumors than in the normal adjacent
benign prostate tissues, and is further down-regulated in
metastatic prostate tumors, indicating that MPC1 down-
regulation may predict a more aggressive prostate can-
cer. More importantly, patients having low levels of
MPC1 expression showed poor prognosis in prostate
cancer [30]. Consistently, we analyzed the prognostic
role of MPC1 and MPC2 on OS of patients with PCA
and found a significant association between MPC ex-
pression and OS of patients, and patients with positive
MPC1 or MPC2 protein expression had a longer survival
time.
Furthermore, multivariate analysis suggested that the
expressions of MPC1 and MPC2 can be independent
predictive factors for PCA. These results are consistent
with the previous studies, suggesting that MPC may
serve as a new therapeutic target for prostate cancer.
Conclusions
In conclusion, we have found low expression of MPC1
and MPC2 in agressive prostate cancer cell line, and also
discovered that negative expression of MPC complex is
significantly associated with unfavorable clinicopatholog-
ical features in PCA samples and shorter survival in
PCA patients. However, the disadvantages in our studies
are the limited number of samples and relatively short
follow-up period, which should be explained with care.
Moreover, the clinical correlation of MPC1 and MPC2
in PCA disclosed herein clearly merits further elucida-
tions. The MPC1 and MPC2 variants and their potential
molecular and biological functions in human prostate
carcinoma are currently under investigation in our
laboratory.
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